Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes that was subsequently found to produce substantial weight loss
Cardiovascular outcomes: TRIUMPH-Outcomes results expected 20282029
PT-141 acts on the brains melanocortin receptors to improve sexual desire, increase sexual arousal, and support visual sexual stimulation responses, which can be especially beneficial for premenopausal women and men with hypoactive sexual desire disorder PDE5 inhibitors enhance erectile response by increasing blood flow, nitric oxide release, and penile muscle relaxation, leading to a penile erection sufficient for sexual intercourse This approach may improve sexual performance and erectile response in patients with mixed psychological aspects and vascular contributors, including those with mild cardiovascular disease or blood flow limitations
Liang Y, Dor V, Rowe CC, Krishnadas N (2024) Clinical Evidence for GLP-1 Receptor Agonists in Alzheimers Disease: A Systematic Review
SP-2297 (Septerna / Novo Nordisk) - small-molecule oral GPCR triple agonist
Constipation affects 20 to 25 percent of patients and can become uncomfortable if not addressed